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Breast cancer proliferation measured on cytological samples: a study by
flow cytometry of S-phase fractions and BrdU incorporation
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Summary Cell kinetics have been shown to be an important predictor ofclinical evolution of operated breast
cancer. We established a method for the estimation of the proliferative activity of tumour cells obtained by
fine needle sampling without aspiration (FNS), using simultaneously S-phase fractions (SPF) measured on
DNA histograms and 5-bromodeoxyuridine (BrdU) labelling index (BLI) measured by flow cytometry.
Biparametric BrdU/DNA flow cytometry could be performed in 122 of 189 (65%) consecutive patients. The
mean BLI of the cytologically malignant FNS (118) was of 3.0 and the median of 2.2%. One hundred and
forty-eight DNA histograms (78%) were suitable for SPF analysis, of which 141 presented-malignant cells,
showing a mean of 4.5 and a median of 3.5%, comparable to BLIs. These results were obtained from
fluorescence peak area histograms with doublet discrimination and background subtraction allowing the
measurements of SPFs as low as 0.4%. An excellent correlation was thus observed between-BLIs and SPFs,
for the 94 cases for which both results were available (r = 0.85). Infrequent discordances (9%) were noted with
SPFs considerably higher than BLIs. Seven patients had three consecutive FNS of their tumour at weekly
intervals before treatment. Some variability in the proportions of multiple subpopulations of tumour cells was
observed on the DNA histograms. In contrast, proliferation indices (SPF or BLI) were reproducible,
suggesting homogeneous growth rates. We conclude that an estimation of the proliferative activity of breast
tumours at any stage of the disease is possible routinely by SPF and/or BLI analysis of FNS. At least one
quantitative proliferation index could be obtained for 91% of patients.
Proliferative activity has consistently been found to be an
important biological predictor of the clinical evolution of
breast cancer (Tubiana et al., 1984; Silvestrini et al., 1985;
Meyer, 1986; Hery et al., 1987). Traditionally, it has been
measured by autoradiography of a radiolabelled precursor
(3H-thymidine) incorporated in tumour-cell DNA.
With the introduction of DNA flow cytometry (FCM), fast
cell-cycle distribution analysis of large numbers of cells has
become available (Barlogie et al., 1982). Retrospective studies
have shown that S-phase fraction (SPF), computed from
DNA histograms, is also a significant prognostic factor
(Hedley et al., 1987; Kallioniemi et al., 1988) and a good
predictor of response to neo-adjuvant chemotherapy (Rem-
vikos et al., 1989). Nevertheless, the possibility ofestablishing
SPF's correctly has been questioned, either from poor
quality- or complex histograms presenting multiple aneuploid
peaks (Meyer et al., 1984; Kallioniemi et al., 1985).
Although 3H-thymidine incorporation in fine needle
aspirates was attempted in the late 70's (Nordenskjold et al.,
1976), very few data have been published on the use of
cytology for the study of breast cancer proliferation. On the
other hand, fine needle samplings (FNS) have been shown to
be suitable for DNA FCM (Spyratos et al., 1987; Remvikos
et al., 1988). The measurement of proliferation in cytological
samples presents a number of advantages. FNS can be
obtained from patients at any stage of the disease, including
non-operable tumours (Zajdela et al., 1987). The information
thus obtained, practically at the time of diagnosis, can be
available for treatment decision. FNS are relatively non-
traumatic and can be repeated during the treatment to
monitor its efficacy.
In a prospective study of feasibility, we developed comple-
mentary methods for assaying SPF and BrdU labelling index
(BLI) in vitro on the same tumour samples. Indeed, the
substitution of 5-bromodeoxyuridine (BrdU) to 3H-thymidine
has been proposed as a more convenient method of measur-
ing DNA synthesis, due to the instant immunofluorimetric
detection (Dolbeare et al., 1983; Schutte et al., 1987).
Tumour cells were obtained directly from the patients by fine
needle sampling without aspiration. The inherent difficulties
of each methodology are discussed in order to define the best
approach for an adequate estimation of the proliferative
activity of each breast cancer before treatment decision.
Materials and methods
One hundred and eighty-nine consecutive patients were sub-
jected to fine needle sampling without aspiration, using 23 or
25 gauge needles (Zajdela et al., 1987). The cytological sam-
ples were expelled in 1 ml of incubating medium: RPMI
(Gibco), 10% foetal calf serum (Calbiochem), 30 pM BrdU
(Sigma). The tubes were incubated at 37°C for 15 min, then
100 yl of DMSO were added and the tubes stored at - 80C.
FNS were processed for DNA-FCM according to a one-
step protocol. The samples were thawed and rinsed with PBS
at 1,500 r.p.m., 5 min. The pellets were resuspended in 600 tl
of PBS, 0.2% Tween 80 (Sigma), 50 lg m -' propidium
iodide (Sigma), 250iLg ml- Ribonuclease A (B6ehringer),
and left at room temperature for 20min.
For BrdU/DNA labelling, cell-rich samples were selected
and fixed in 70% ethanol. In all cases, at least 50,000 cells
were kept for DNA analysis as above. The fixed samples
were centrifuged, digested with 3 ml of pepsin (Sigma)
0.5 mg ml-' dissolved in 30 mM HCI at 37°C for 30 min and
denatured in HCI 2N for 20 min. After two rinses with PBS
and one with BrdU buffer: PBS, 0.5% Tween 20 (Sigma),
0.5% normal goat serum, 20 mM Hepes, pH 7.4, 500 yt1 of the
rat monoclonal antibody, clone BU1/75 (Sera-Lab, Crowley
Down, UK) at a 1/25 dilution were added to each sample for
1 h. The tubes were then centrifuged after the addition of
5 ml of PBS and resuspended in 300 gl of anti-rat IgG-FITC
(Southern Biotech, Birmingham, USA) diluted to 1/50 for
30 min. Free antiserum was eliminated by centrifugation and
the pellets suspended in PBS, 25 tcg ml- of propidium iodide
(Sigma) and stored on ice, in the dark until analysis (within
1 h).
Cytocentrifuged slides were prepared with aliquots of the
suspension used for DNA-FCM (10"-10' cells), on a Cyto-
spin 2 (Shandon): 5 min 700 r.p.m. Immunocytochemical
BrdU staining was performed on slides fixed overnight in
70% ethanol at 4°C. The slides were air-dried, denatured in
NaOH 0.07 N for 2 min and neutralised in sodium borate
buffer, pH 8.8. The anti-BrdU monoclonal antibody (Becton-
Dickson) was applied diluted to 1/10 for 1 h at room
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temperatue. The ABC kit (Vector) wyas used to reveal the
staining with diaminobenzidine (Sigma) as substrate and cell
nuclei were counterstained with haematoxylin.
FCM analysis (DNA or BrdU/DNA) was performed on a
FACSTAR (Becton-Dickinson) equipped with a doublet dis-
crimination module. Settings for green (BrdU) and red
fluoresence (PI) were linear. BLIs were always determined
from density dot plots after elimination of doublets. DNA-
ploidy was determined using human lymphocytes as external
standard. Fluorescence data were collected for 10,000 cells
from each sample. SPFs were computed according to the
rectangular 'Model of Baisch (Baisch et at., 1982) with the
Cellfit software (Becton-Dickinson), including systematic
background subtraction. SPFs were computed on the aneu-
ploid portion of the histograms whenever possible. The same
applied to BLI determinations. When the aneuploid cells
constituted less than 50% of the histogram, a total and an
aneuploid BLI were computed. The corresponding cyto-
logical smears were also inspected to establish the composi-
tion of each sample (proportion of tumour cells).
Histopathological grading (Bloom & Richardson, 1957)
was performed on standard paraffin-embedded haematloxylin-
eosin stained sections of corresponding surgical samples or
drill biopsies. Steroid hormone receptor assays were per-
formed on surgical samples or fine needle samples as
previously described (Magdelenat et al., 1987a,b).
Results
Seven of the 189 lesions were found cytologically benign. All
were diploid with low SPFs (0.7-2.0%) and BLI (0.3-1.1%).
Six samples contained an insufficient number of cells and
were considered non-informative (3%). DNA FCM of the
176 cytologically malignant FNS yielded only one histogram
with a CV >8.0%, considered non-interpretable, 46 diploid
(26%), 104 single peak aneuploid and 25 multiploid (14%)
tumours. SPFs could be computed in 141 cases (80%). The
quality of the BrdU incorporation was first verified on
immunocytochemically stained slides (Figure 1). These were
routinely prepared from the propidium iodide-stained suspen-
sions after DNA FCM analysis. We had previously verified
that the results were equivalent to those obtained on an
aliquot before processing the sample for DNA analysis (not
shown).
Samples were selected for BrdU-FCM analysis if they con-
tained more than approximately 2.1l0' cells. One hundred and
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Figure 1 Representative immunocytochemically stained cytocen-
trifuged slide (initial magnification: x 200).
twenty-one were thus prepared, of which 118 yielded inter-
pretable cytograms. Representative cases are shown in Figure
2. The resolution between BrdU-positive and -negative cells
was excellent. DNA histograms obtained by the one-step
method were identical to those of doubly stained samples in
terms of proportion of different subpopulations and DNA
indices. In some cases the samples stained for BrdU showed
larger CV's, possibly due to the denaturing procedure, but
this was mostly limited to cell-poor samples.
The complexity of DNA histograms resulted in a number
of constraints limiting the applicability of each proliferation-
related parameter. Thus, the histograms were classified ac-
cording to the composition of the corresponding samples
(presence of normal cells) as established by cytology and the
proportion of aneuploid cells. Histograms presenting less
than 50% aneuploid cells and a large proportion of normal
cells upon diagnostic slide inspection were classified as minor
aneuploid. If the normal component was minor then histo-
grams were considered as diploid/aneuploid. As can be seen
in Table I, SPF could be computed in all diploid and almost
all cases presenting more than 50% aneuploid cells in the
histograms. On the other hand, when the aneuploid sub-
population was minor or when there was more than one
aneuploid peaks, considerably fewer histograms were suited
for SPF analysis.
The proportion of cases informative for BLI was similar in
the different histogram types and particularly high for multi-
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Figure 2 BrdU/DNA cytograms from FNS of a breast lesion (left) and the axillary metastasis (right) of the same patient, showing
similar DNA indices (respectively 1.67 and 1.64) and proliferative characteristics (aneuploid BLIs of 5.8 and 6.2%). The units on
the x-(DNA) and y-axis (BrdU) are arbitrary channel numbers. The contour plots were gated on the basis of the DNA histograms.
Diploid cells were set around channel 10 and BrdU staining occupied the full scale.
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Table I Proliferation indices and DNA histogram type
Proliferation index
SPF BLI None Total
Diploid 46 30 0 46
Multiploid 10 22 3 25
Major aneuploid 69 46 0 72
Minor aneuploid 2 6 2 9
Diploid aneuploid 14 14 5 23
Non informative - - - 7
Benign 7 4 - 7
Total 148 122 10 189
ploid ones. In samples containing both diploid and aneuploid
tumour cells, it was generally found that the diploid com-
ponent presented less BrdU staining than the aneuploid one,
but some exceptions were observed (Figure 3). Multiploid
samples could also be analysed as can be seen in Figure 4.
Another advantage of the BrdU/DNA analysis was the possi-
bility of quantitating the staining of a minor sub-population.
This is shown in Figure 5, which represents a cytogram of an
FNS from an axillary lymph node containing cytologically
less than 15% tumoral cells, where S-phase could not be
reliably derived. A BLI of 9.6% was computed by gating on
the hypertetraploid cell population.
The frequency distribution of SPFs is shown in Figure 6.
The mean for the 141 cases was of 4.5% and the median of
3.5% (range 0.4-13.5%). A slightly different distribution was
obtained for BLIs (Figure 7), with under-representation of
the 7-9% values. The mean was of 3.0% and the median of
2.2% (range 0.3-17.4%).
SPF and BLI were obtained from the same sample in 94
cases. A highly significant correlation was found between the
two indices (r = 0.85), as can be seen in Figure 8. Eight
samples showed quantitatively discordant values with SPF
more than double the value of the BLI. In these cases, the
immunocytochemically-stained slides were carefully inspected
and only two were found to present significantly higher
labelled fractions as can be seen in Figure 9. The general
comparison of BLI determinations yielded a poorer correla-
tion than BLI (FCM) vs SPF (r = 0.75).
In order to verify the representativity of the FNS as
regards tumour heterogeneity, seven patients were submitted
to three samplings at weekly intervals. As shown in Figure
10, striking differences could be observed in the DNA histo-
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Figure 3 Bivariate cytogram showing Brdt
diploid (channel 13) and the peritetraploid
total BLI was of 6.7%. Only the data gatl
DNA histogram appear on the contour p
r-
LL
. ... .. .............
60
30
0- . 1.
0 30
FL2
60
Figure 4 DNA histogram and BrdU/DNA cytogram of a multi-
ploid breast cancer, presenting three different DNA peaks. The
DNA histogram represents the ungated data, and the contour
plot the data including the diploid cells and the G2 peak of the
population of highest DNA index.
grams. Two of the seven tumours were found diploid in all
three FNS, while the remaining five were always aneuploid.
However, multiploidy was observed for four patients, with
variable representation of the clones in the repetitive FNS
(Table II). On the other hand, proliferation was found to be
a rather stable characteristic of the tumours, as were the
differences between SPF determinations and BLIs.
SPFs and BLIs were found to be highly correlated to
histopathological grade (SBR) and inversely correlated to
estrogen and progesterone receptor content (Table III). Di-
ploid tumours displayed significantly reduced proliferation.
Interestingly, BLI analysis of multiploid lesions revealed an
average of 2.5%, compared to 1.6 for the diploid and 3.8 for
the single-peak aneuploid.
Discussion
The proliferation of tumour cells in breast cancer specimens
was initially studied by autoradiography after 3H-thymidine
incorporation. Different series of results have been published
with median values ranging from 2 to 7% of labelled cells
(reviewed in Meyer et al., 1984).
The most simple and rapid method for cell-kinetic analysis
of tumour specimens would at present be DNA-FCM. How-
ever the functional assays, based on DNA precursor-
incorporation, are still currently considered as the reference.
I I I I As a matter of fact, a number of drawbacks about the
60 DNA-FCM determination have been pointed out, such as
the applicability of mathematical models to complex histo-
J staining for both the grams. Studies on breast cancer have shown that SPFs can
cells (channel 25). The be obtained in 65-80% of cases (Kute et al., 1985; Kal-
ed on the basis of the lioniemi et al., 1987; Hedley et al., 1987; Dressler et al.,
lot. 1988).
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The validity of absolute values has also been questioned.
Statistical results from DNA FCM-derived SPFs have been
generally found higher than TLIs (Meyer et al., 1984),
although McDivitt et al. have shown an excellent correlation
between SPFs and TLI on the same specimens (McDivitt et
al., 1986).
The SPF values obtained in the present study are probably
the lowest reported, but correspond quite reasonably to the
aforementioned TLIs. It should be pointed out that 'state of
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Figure 5 DNA histogram and BrdU/DNA cytogram (both
represent the total data set) of a cytological sample from an
axillary lymph node. On the corresponding diagnostic slide, it
was estimated to contain less than 15% tumour cells, which
correlates with the hypertetraploid peak on the DNA histogram.
The aneuploid BLI was estimated by setting a gate based on the
DNA histogram, excluding as far as possible data points corres-
ponding to lymphocytes.
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Figure 7 Frequency distrubution of BLIs derived from BrdU/
DNA cytograms of 118 breast cancers.
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Figure 8 Comparison of SPFs and BLIs obtained simultaneously
on the same cytological samples for 94 patients. The straight line
represents results from linear regression analysis. The vertical and
horizontal lines correspond to the median SPF and BLI values.
Thus only six cases were found in the lower right and upper left
(discordant) quadrants.
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Figure 6 Frequency distribution of SPFs computed form DNA
histograms of 142 breast cancers.
Figure 9 Comparison of BLIs obtained by scoring immuno-
peroxidase-stained nuclei on cytocentrifuged slides to those
obtained by FCM. The linear regression line is superimposed to
the ddta points. Seven of the eight points for which discordant
SPF and FCM-BLI values had been obtained, appear as full
squares.
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Figure 10 DNA histograms of three repetitive FNS obtained at
weekly intervals from the same patient.
the art' notions in DNA-FCM, such as doublet discrimina-
tion and the use of red fluorescence peak area histograms
rather than peak height (Dressler & Bartow, 1989), were
applied in the present study. However, the most important
correction factor was background subtraction. In this respect,
our results agree with those of Haag et al. (1987), who were
the first to apply this type of correction to DNA histograms
of breast cancer specimens. In spite of these technical im-
provements, SPFs could be calculated for only 141 out of
176 patients (80%), and for 148 out of 183 if non-malignant
specimens were included. Of the 35 cases for which no SPF
could be obtained (except the case for which the quality of
the histogram was judged insufficient), two corresponded to
histograms with excessive debris, one to a single hypodiploid
GI peak, 16 to samples with minor aneuploid clones and 15
to multiploid tumours.
A frequent criticism with regard to SPF values has also
been its inability to distinguish cells that are actively syn-
thesising DNA from the putative S-quiescent cells (Darzyn-
kiewicz et al., 1980). BrdU incorporation has been found to
correlate quite well with 3H-thymidine labelling index in non-
Hodgkin's lymphoma (Silvestrini et al., 1988). Being a non-
isotopic method, BrdU labelling presents the advantage of
simpler processing of specimens. We have studied BrdU
incorporation in the same series of cytological samples where
DNA-FCM histograms were obtained, in order to (i) in-
crease the proportion of patients for whom proliferative
status could be obtained, and (ii) compare the quantitative
results of the different methods. Such samples are already
dissociated, so that incubation with BrdU starts only seconds
after the cells have been withdrawn from the tumour.
The ultimate goal being to introduce proliferative activity
as one of the parameters used for treatment decision, a
number of conditions should be met:
(1) The assay should be easily performed in routine. This
was achieved here by using a short incubation time, compat-
ible with the duration of the FNS procedure for each patient.
The quality of the staining was found excellent both after
immunocytochemical staining on cytocentrifuged slides and
bipametric BrdU/DNA FCM-analysis. At the concentration
of 300tM BrdU, neither an increase in the volume of incuba-
tion nor a more prolonged exposure seemed to be necessary.
In fact, staining was apparent within 10 min of incubation,
even at room temperature. Although most cytocentrifuged
samples were of good quality, the morphological distinction
between normal and malignant cells was often poor on
stained slides, leading possibly to an underestimation of the
BLI. In the analysis of the FCM-derived BLIs, the dual-
parameter cytograms allowed at least the distinction of di-
ploid vs aneuploid or multiploid cell populations and their
respective labelled fractions. Indeed we observed that in
tumours showing both diploid and aneuploid cell populations
(verified cytologically), total BLI was often reduced com-
pared to the one computed after gating on the sole aneuploid
cells. One hundred and twenty-five of the 189 cytological
samples contained a sufficient number of cells for FCM-BLI
analysis, 122 yielded interpretable cytograms (118 corre-
sponding to cytologically malignant lesions). The range of
Table H Comparison of FCM findings in repetitive FNS
Case I Case 2 Case 3 Case 4 Case 5 Case 6 Case 7
0.98 1.17/1.57/2.04/2.25 1.71/1.86 1.78 1.65 1.08 1.00
DNA index 0.98 (1.10)/2.20 1.70 1.80 1.65/1.80 1.08/1.88 1.00
1.00 1.10/1.65/2.18 1.65/1.82 1.80 1.80 1.06 1.00
2.7 ND ND 9.2 4.1 9.8 1.3
SPF 2.4 1.8 3.1 7.8 2.8 ND 1.0
2.5 ND ND 8.5 ND 7.8 1.7
1.9 2.0 1.5 ND 3.0 ND ND
BLI 0.9 ND 1.4 1.7 3.1 3.3 ND
ND ND ND 1.6 2.1 3.5 1.5
ND: not determined.
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Table III Proliferation vs histopathological grade, SHR and DNA ploidy
SPF BLI
n % Significance n % Significance
SBR Grade I 14 2.0 Variance 11 1.5 Variance
II 64 3.9 P <0.001 50 2.3 P <0.0002
III 23 6.1 21 5.1
ER + 88 3.6 P <0.0001 75 2.3 P <0.000l
- 25 7.3 t-test 21 5.4 t-test
PgR + 62 3.5 P <0.0001 55 2.4 P <0.002
- 50 5.9 t-test 42 4.1 t-test
DNA ploidy Diploid 46 2.6 P <0.0001 30 1.6 P <0.001
Aneuploid 95 5.4 t-test 88 3.5 t-test
the latter was 0.3-17.4%, with a mean of 3.0 and a median
of 2.2%, values that agree quite well with TLIs in the
literature, despite the very short incubation time used in our
study.
(2) The information should be obtained in a large majority
of patients. We have shown that for the 189 consecutive
patients, both SPF and BLI could be obtained in 52%, SPF
alone in 26% and BLI alone in 13%, with at least one
quantitative index of proliferative activity available for 91%
of the patients. However, it was still to be shown whether
one of the indices was sufficient to characterise the pro-
liferative activity of a given tumour. Indeed, the frequency
distributions for SPFs and BLIs were found slightly different
but the difference was limited to the 70-80th percentile.
This result was relatively surprising since the values for the
94 cases for which both SPF and BLI were obtained simul-
taneously from dual parameter cytograms, showed a good
correlation (r = 0.85, P <0.0001). A possible bias introduced
by the selection of samples for FCM BLI analysis based on
the number of cells in hte FNS cannot be excluded. Another
explanation could reside in the fact that BLIs can be deter-
mined for cases where SPF is inapplicable. Thus each index
characterises a slightly different population of breast cancers.
(3) The procedure should provide reliable results. Our
study revealed that whenever SPFs and BLIs were available
for the same cases, their values were closely correlated. Less
than 10% discordant values were observed. However, for
clinical purposes a discrete classification should be more
useful than continuous values. If the patients were simply
classified as above or below median, six presented discordant
classification and only two of these had clearly divergent
values. Thus despite the slight differences in the frequency
distributions, any of the two indices of proliferative activity
should provide reliable information, using the appropriate
cut-off values for each distribution.
Still, two questions remained concerning the adequacy of
FNS for DNA and BrdU incorporation studies. The first
concerns cell death induced by FNS, but the infrequent
observation of cases showing SPFs considerably higher than
BLI indicates a minor influence of a possible trauma caused
by the FNS. The second addressed tumour heterogeneity and
the representativity of sampling relative to the tumour mass.
Repeated samplings were performed on seven patients, as
already attempted by others (Mullen & Miller, 1989).
Modifications of the DNA histograms were observed in four
out of seven, consisting in variable representation ofmultiple
DNA peaks. Thus, multiploidy may have been underesti-
mated in breast cancer. Although the number of patients is
small, both SPF and BLI were fairly reproducible, as were
the discordances between the two. This consistency of the
proliferation indices, with variable representation of
genetically different clones deserves further investigation
regarding tissular kinetic homeostasy.
It has recently been shown that in vivo kinetic information
can be obtained after BrdU infusion (Hoshino et al., 1985;
Wilson et al., 1988). The latter paper has shown that by
delaying the biopsy relative to the injection, not only label-
ling indices but also potential doubling times can be
estimated from a single sample. But our method, based on
FNS, at least for breast cancer patients, may be preferable
because of its simplicity and its applicability without prior
diagnosis of cancer. This information on tumour prolifera-
tion, available at diagnosis should prove valuable for prog-
nosis and treatment decision.
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